[Oral bisphosphonates and CTX. New methods for assessing the degree of risk in maxillo-mandibular osteonecrosis].
Blanc
J-L
JL
Chossegros
C
C
D000284:Administration, Oral; D015415:Biomarkers / Q000032:analysis; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000009:adverse effects*; D024042:Collagen Type I / Q000032:analysis*; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D008336:Mandibular Diseases / Q000139:chemically induced*; D008439:Maxillary Diseases / Q000139:chemically induced*; D010020:Osteonecrosis / Q000139:chemically induced*; D010455:Peptides / Q000032:analysis*; D012307:Risk Factors
D015415:Biomarkers; D050071:Bone Density Conservation Agents; D024042:Collagen Type I; D004164:Diphosphonates; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide